Signition LP’s TherapeuticsMD TXMD Stock Holding History

Signition LP’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-224	Closed	-$70K	–	402
2018 Q2	$70K	Buy	+224	New	+$68.4K	0.04%	246

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Signition LP's TXMD Position: Q3 2018 in Review

Signition LP sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 224 shares — an estimated $70K sold.

Signition LP first reported a position in TXMD in Q2 2018 and held it in 1 quarter. The position peaked at $70K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

Signition LP reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
Signition LP sold 224 TherapeuticsMD shares in Q3 2018, an estimated $70K.
Signition LP first reported a position in TherapeuticsMD in Q2 2018 and held it in 1 quarter.
Signition LP's TherapeuticsMD position peaked at $70K in Q2 2018.
155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Signition LP's 13F filing for Q3 2018, filed 1 Nov 2018.